Dataset for: Developing HIV risk prediction tools in four African settings

The study was set up at sites in Masaka, Uganda; Durban, South Africa; Maputo, Mozambique; Mbeya and Dar es Salaam, Tanzania, to prepare a population of HIV negative individuals at risk of acquiring HIV for possible participation in the PrEPVacc HIV vaccine efficacy and pre-exposure prophylaxis trial.

It contains information on demographic, HIV risk behavioural characteristics, HIV prevalence at screening and incidence during follow up, among participants.